On July 23 and 24, 2026, the Pharmacy Compounding Advisory Committee recommended six peptides for the Section 503A Bulks List. The vote margins were narrow: BPC-157, KPV, and TB-500 passed 8-6 with one abstention. MOTS-c passed 7-5 with two abstentions. Epitalon and Semax followed the next day. Emideltide failed.
The committee overrode FDA career scientists, who unanimously recommended against all seven substances under review. The staff briefing materials characterized the available studies, including five trials of BPC-157, as short in duration, small in sample size, and insufficient to establish safety or effectiveness for the indications under review. BPC-157's only human clinical evidence is a decades-old meeting abstract that was never published, according to AJMC's report on the panel decision.
The vote carries no statutory weight. None of the six peptides has been added to the 503A Bulks List, and none is an FDA-approved drug. Scott Brunner, CEO of the Alliance for Pharmacy Compounding, stated that FDA must formally adopt the advisers' recommendations before the peptides may be legally compounded. That requires notice-and-comment rulemaking: a proposed rule, a public comment , and a final rule. The agency has set no timeline.
The enforcement posture remains unchanged. On February 6, 2026, FDA separately restricted the active pharmaceutical ingredients used in mass-marketed compounded semaglutide and tirzepatide and moved against marketing that described those compounded products as generic or equivalent to FDA-approved versions. That action targeted the 503B outsourcing pathway. The July PCAC vote concerns the 503A bulks process, a separate statutory mechanism. AJMC's explainer on the reversal documents both tracks.
For pharmacies and cross-border API importers, the gap between the advisory vote and any final rule creates a specific liability problem. Trade literature is already advising facilities to scale for peptide compounding growth. Modular Devices, a cleanroom equipment vendor, published guidance in August 2026 telling pharmacies to prepare for peptide compounding expansion and scale facilities quickly. That commercial advice addresses market opportunity. It does not resolve the statutory threshold.
A pharmacy that expands cleanroom capacity or secures API supply in anticipation of a final rule accepts enforcement risk that no interim guidance currently mitigates. Compounding BPC-157, TB-500, MOTS-c, Semax, KPV, or epitalon remains prohibited under federal law until FDA completes rulemaking.
The committee's composition drew conflict-of-interest scrutiny. Eight new members were appointed before the July meeting, several with financial ties to businesses that sell or administer peptides, as documented in prior reporting on the reconstituted panel. An independent UCLA Health review of six popular peptides found little evidence supporting promoted uses and flagged potentially concerning safety issues.
The statutory threshold has not moved. A panel vote changes nothing until the FDA publishes a final rule.
Related reporting explores fda panel's narrow vote leaves bpc-157 and semax in regulatory limbo, and fda splits peptide path.
